Precede was founded by Rehan Verjee, Sylvan Baca, Toni Choueiri, Matthew Freedman in 2021.

Who are Precede's investors?

Precede's investors include 5AM Ventures, Illumina Ventures, OUP (Osage University Partners), Alexandria, Lilly Asia Ventures, S28 Capital.

Where is Precede headquartered?

Precede is headquartered in Boston, US.

Precede

Boston, US · Founded 2021 · 65 employees on LinkedIn · 12 known investors

Find your way into Precede

Paths you didn't know you had: your email and LinkedIn already hold routes to the Precede team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Precede Biosciences develops a blood-based diagnostic platform that profiles gene expression from cell-free DNA to reveal disease biology at the transcriptional level for drug developers and clinical trials. The platform enables non-invasive patient selection and longitudinal tracking of disease mechanisms in oncology and other therapeutic areas.

AI & Machine Learning Biotech Digital Health

Founders & leadership

Precede was founded in 2021 by Rehan Verjee, Sylvan Baca, Toni Choueiri, and Matthew Freedman.

Rehan VerjeeCo-Founder, Chief Executive Officer, Board Director

Sylvan Baca Co-Founder; Assistant Professor of Medicine, Dana-Farber Cancer InstituteSylvan Baca is an Assistant Professor of Medicine and physician-scientist at Dana-Farber Cancer Institute with expertise in computational biology and epigenomics. He is co-founder of Precede Biosciences, which develops blood-based diagnostics for gene expression profiling in oncology and clinical trials.

Toni ChoueiriCo-Founder; Director, Lank Center for GU Oncology, Dana-Farber Cancer Institute

Matthew FreedmanCo-Founder; Professor of Medicine, Dana-Farber Cancer Institute

Investors · 12

5AM Ventures✓ confirmed by PrecedeSan Francisco · $100K – $4M

How we know: the company's own site · 5AM Ventures's portfolio page · a partner's Signal profile · citybiz.co · Not right? Tell us

Illumina Ventures✓ confirmed by PrecedeFoster City

How we know: Illumina Ventures's portfolio page · a partner's Signal profile · funding news · citybiz.co · the VCSheet dataset · Not right? Tell us

OUP (Osage University Partners)listed by OUP (Osage University Partners)Bala Cynwyd · $1M – $20M

How we know: OUP (Osage University Partners)'s portfolio page · Not right? Tell us

AlexandriareportedPasadena

How we know: citybiz.co · Not right? Tell us

Lilly Asia VenturesreportedHong Kong

How we know: citybiz.co · Not right? Tell us

S28 CapitalreportedSan Francisco · $1M – $5M

How we know: citybiz.co · Not right? Tell us

Also in the syndicate · 6

Binney Street CapitalBristol Myers SquibbLabcorp Venture FundMirae Asset CapitalMirae Asset Capital Life ScienceUPMC Enterprises

Funding

SEC filings, press & company announcements

Undisclosed amountSeries BJan 2026
28 Capital, 5AM Ventures, Alexandria Venture Investments, Binney Street Capital, Bristol Myers Squibb, Illumina Ventures, Labcorp Venture Fund, Lilly Asia Ventures, Mirae Asset Capital, Mirae Asset Capital Life Science, Osage University Partners, UPMC Enterprises
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Related companies · 3

Precision BioSciencesPrecision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).

LabcorpLabCorp provides diagnostic testing services and clinical trial recruitment solutions that connect patient insights to drug development for healthcare providers.

IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.

Companies working in the same space as Precede.

In the news

Precede Biosciences Raises $83.5M in Financing | citybizcitybiz.co · Jan 2026

Precede Biosciences Secures $83.5M in Total Financing to Scale Next-Generation Precision Diagnostics Platform - BioSpacebiospace.com · Jan 2026

Precede Biosciences Emerges From Stealth With $57M in Fundingfinsmes.com · Oct 2023

Frequently asked questions

What does Precede do?: Precede Biosciences develops a blood-based diagnostic platform that profiles gene expression from cell-free DNA to reveal disease biology at the transcriptional level for drug developers and clinical trials. The platform enables non-invasive patient selection and longitudinal tracking of disease mechanisms in oncology and other therapeutic areas.
Who founded Precede?: Precede was founded by Rehan Verjee, Sylvan Baca, Toni Choueiri, Matthew Freedman in 2021.
Who are Precede's investors?: Precede's investors include 5AM Ventures, Illumina Ventures, OUP (Osage University Partners), Alexandria, Lilly Asia Ventures, S28 Capital.
Where is Precede headquartered?: Precede is headquartered in Boston, US.